Alzamend Neuro, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Alzamend Neuro, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 5,199% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Alzamend Neuro, Inc. made a loss over the last year. Alzamend Neuro, Inc. owes $0.32 for every $1 it owns. Alzamend Neuro, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Apr 2026.
P/E ratio
LossAlzamend Neuro, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.93The share price is 0.93 times Alzamend Neuro, Inc.'s book value per share, lower than 80% of Healthcare companies in United States.
Market cap
$5 MThe total market value of all of Alzamend Neuro, Inc.'s shares at today's price (share price × number of shares), smaller than 93% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$6 MWhat Alzamend Neuro, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Jul 2026).
Book value per share
$1.20Net worth divided by the number of shares. The share price of $1.12 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-163.2%Alzamend Neuro, Inc. lost 163.2% of its shareholders' money over the last year, lower than 81% of Healthcare companies in United States.
Owes vs Owns
0.32×Alzamend Neuro, Inc. owes $0.32 for every $1 it owns (low), lower than 58% of Healthcare companies in United States.
Dividend yield
NoneAlzamend Neuro, Inc. does not currently pay a dividend.
Profit growth
LossAlzamend Neuro, Inc. made a loss in each of the last two years.
Interest cover
Not coveredAlzamend Neuro, Inc.'s operating profit did not cover its interest costs in the year to Apr 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Alzamend Neuro, Inc.: $5 M ÷ $6 M (31 Jul 2026) = 0.9.
What is Alzamend Neuro, Inc.'s return on equity?
Alzamend Neuro, Inc. lost 163.2% of its shareholders' money over the last year, lower than 81% of Healthcare companies in United States.
How much does Alzamend Neuro, Inc. owe compared with what it owns?
Alzamend Neuro, Inc. owes $0.32 for every $1 it owns (low), lower than 58% of Healthcare companies in United States.
Does Alzamend Neuro, Inc. pay a dividend?
No. Alzamend Neuro, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.